Known targets — ChEMBL curated mechanism
The experimentally established mechanism targets of Chlorpromazine. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | DRD2 known ✓ | P14416 | 5/20 | 1.00 |
| ▸ | DRD3 known ✓ | P35462 | 5/20 | 1.00 |
| ▸ | DRD4 known ✓ | P21917 | 3/20 | 1.00 |
| ▸ | HTR2A known ✓ | P28223 | 3/20 | 1.00 |
| ▸ | CYP1A2 | P05177 | 9/20 | 1.00 |
| ▸ | CYP2D6 | P10635 | 9/20 | 1.00 |
| ▸ | HTR1A | P08908 | 6/20 | 1.00 |
| ▸ | LMNA | P02545 | 6/20 | 1.00 |
| ▸ | MAPT | P10636 | 6/20 | 1.00 |
| ▸ | TP53 | P04637 | 6/20 | 1.00 |
| ▸ | CYP2C19 | P33261 | 5/20 | 1.00 |
| ▸ | SMN1; SMN2 | Q16637 | 5/20 | 1.00 |
| ▸ | CHRM2 | P08172 | 5/20 | 1.00 |
| ▸ | ADRA2A | P08913 | 5/20 | 1.00 |
| ▸ | CHRM1 | P11229 | 5/20 | 1.00 |
| ▸ | DRD1 | P21728 | 5/20 | 1.00 |
| ▸ | SLC6A2 | P23975 | 5/20 | 1.00 |
| ▸ | SLC6A4 | P31645 | 5/20 | 1.00 |
| ▸ | ADRA1A | P35348 | 5/20 | 1.00 |
| ▸ | OPRM1 | P35372 | 5/20 | 1.00 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Chlorpromazine SCHEMBL8321 | 1.00 | CYP1A2 (1.00) | CYP1A2CYP2D6HTR1ALMNAMAPT | |
| Chlorpromazine SCHEMBL29358018 | 1.00 | CYP1A2 (1.00) | CYP1A2CYP2D6HTR1ALMNAMAPT | |
| Chlorpromazine SCHEMBL41771 | 0.99 | CYP1A2 (1.00) | CYP1A2CYP2D6HTR1ALMNAMAPT | |
| Chlorpromazine SCHEMBL8503036 | 0.99 | CYP1A2 (1.00) | CYP1A2CYP2D6HTR1ALMNAMAPT | |
| Chlorpromazine SCHEMBL27940552 | 0.99 | CYP1A2 (0.97) | CYP1A2CYP2D6HTR1ALMNAMAPT | |
| Chlorpromazine SCHEMBL23326209 | 0.99 | CYP1A2 (1.00) | CYP1A2CYP2D6HTR1ALMNAMAPT | |
| Chlorpromazine SCHEMBL29351728 | 0.99 | CYP1A2 (1.00) | CYP1A2CYP2D6HTR1ALMNAMAPT | |
| Chlorpromazine SCHEMBL5483904 | 0.99 | CYP1A2 (1.00) | CYP1A2CYP2D6HTR1ALMNAMAPT | |
| Chlorpromazine SCHEMBL29714121 | 0.99 | CYP1A2 (1.00) | CYP1A2CYP2D6HTR1ALMNAMAPT | |
| Chlorpromazine SCHEMBL27869706 | 0.99 | CYP1A2 (0.97) | CYP1A2CYP2D6HTR1ALMNAMAPT |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 134 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-3994238-B1 | LUBRICATING COMPOSITIONS CONTAINING BASIC ASHLESS ADDITIVES | LUBRIZOL CORP (US) | 2024-03-13 | — | — | EP | claimed |
| WO-2022214855-A1 | USE OF NITAZOXANIDE TO PREPARE A MEDICINAL PRODUCT TO PREVENT OR TREAT CORONAVIRUS SARS-COV-2 INFECTION | SIEGFRIED RHEIN, S.A. DE C.V. (MX) | 2022-10-13 | — | — | WO | claimed |
| US-20260125378-A2 | Heterocyclic Compounds | BEONE MEDICINES I GMBH (CH) | 2026-05-07 | — | — | US | disclosed |
| EP-3731848-B1 | TARGETING THE CBM SIGNALOSOME COMPLEX INDUCES REGULATORY T CELLS TO INFLAME THE TUMOR MICROENVIRONMENT | MASSACHUSETTS GEN HOSPITAL (US) | 2026-04-15 | — | — | EP | disclosed |
| US-12552815-B2 | Boronic acid derivatives and synthesis, polymorphic forms, and therapeutic uses thereof | QPEX BIOPHARMA, INC. (US) | 2026-02-17 | — | — | US | disclosed |
| US-20260014100-A1 | Compositions and Methods for Treating Bleeding and Bleeding Disorders | YEWSAVIN INC (US) | 2026-01-15 | — | — | US | disclosed |
| US-12343317-B2 | Compositions and methods for treating bleeding and bleeding disorders | YewSavin, Inc. (US) | 2025-07-01 | — | — | US | disclosed |
| US-20250179130-A1 | METHODS AND SYSTEMS FOR DESIGNING AND/OR CHARACTERIZING SOLUBLE LIPIDATED LIGAND AGENTS | ON TARGET THERAPEUTICS LLC | 2025-06-05 | — | — | US | disclosed |
| WO-2025071390-A1 | LIPID-BASED FORMULATION CONTAINING HELENALIN FOR TOPICAL OPHTHALMIC USE WITH APPLICATION IN THE MODULATION OF THE INFLAMMATORY PROCESS OF THE OCULAR SURFACE AND IN THE TREATMENT OF DRY EYE | CENTRO DE RETINA MÉDICA Y QUIRÚRGICA, S.C. (MX) | 2025-04-03 | — | — | WO | disclosed |
| US-20250101104-A1 | BISPECIFIC MOLECULE WITH TUNABLE AFFINITY TO A TARGETED ANTIGEN | MABSWITCH INC (US) | 2025-03-27 | — | — | US | disclosed |
| EP-3694864-B1 | BORONIC ACID DERIVATIVES AND SYNTHESIS THEREOF | QPEX BIOPHARMA INC (US) | 2025-03-05 | — | — | EP | disclosed |
| US-11286270-B2 | Boronic acid derivatives and synthesis thereof | QPEX BIOPHARMA, INC. (US) | 2022-03-29 | — | — | US | disclosed |
| CN-112874410-B | Power equipment transport vehicle | 国网湖北省电力有限公司鄂州供电公司 | 2022-03-25 | — | — | CN | disclosed |
| CN-112352719-B | Marine aquaculture platform | 威海海洋职业学院 | 2022-03-22 | — | — | CN | disclosed |
| CN-215993847-U | Cleaning equipment | 北京石头世纪科技股份有限公司 | 2022-03-11 | — | — | CN | disclosed |
| CN-215877418-U | A high-efficient mixer for honey stirring | 四川健生堂农业开发有限公司 | 2022-02-22 | — | — | CN | disclosed |
| CN-113079649-B | Film peeling mechanism and cover film laminating equipment | 江苏创源电子有限公司 | 2022-02-18 | — | — | CN | disclosed |
| CN-215828738-U | Quick extraction and collection equipment for preventing extracted stem cells from being polluted | 广东省人民医院 | 2022-02-15 | — | — | CN | disclosed |
| CN-215825057-U | But angle grinder cutting multi-angle adjusts bottom plate device | 童惠广 | 2022-02-15 | — | — | CN | disclosed |
| CN-215704183-U | Mask material belt welding device | 山东华滋自动化技术股份有限公司 | 2022-02-01 | — | — | CN | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20260125378-A2 | Heterocyclic Compounds | NFATC1, CD4, MALT1 | DRD2 2670/4885DRD3 1925/4885DRD4 1213/4885 |
| US-20260014100-A1 | Compositions and Methods for Treating Bleeding and Bleeding Disorders | SERPINC1, F2, F13B | DRD2 3077/4885DRD3 2542/4885DRD4 3662/4885 |
| US-12343317-B2 | Compositions and methods for treating bleeding and bleeding disorders | SERPINC1, SERPINE1, SERPINH1 | DRD2 4571/4885DRD3 3907/4885DRD4 4398/4885 |
| US-11286270-B2 | Boronic acid derivatives and synthesis thereof | BTD, BLVRB, BLK | DRD2 3588/4885DRD3 3139/4885DRD4 3976/4885 |
| US-20250179130-A1 | METHODS AND SYSTEMS FOR DESIGNING AND/OR CHARACTERIZING SOLUBLE LIPIDATED LIGAND AGENTS | LDLR, HDLBP, LIPG | DRD2 3481/4885DRD3 3138/4885DRD4 3883/4885 |
| US-12552815-B2 | Boronic acid derivatives and synthesis, polymorphic forms, and therapeutic uses thereof | BBC3, BLK, BRCA1 | DRD2 3144/4885DRD3 1514/4885DRD4 3108/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.